PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Overview of attention for article published in New England Journal of Medicine, June 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 73 news outlets
blogs: 4 blogs
policy: 1 policy source
twitter: 311 X users
patent: 31 patents
facebook: 7 Facebook pages

wikipedia: 1 Wikipedia page
googleplus: 1 Google+ user
reddit: 1 Redditor
f1000: 1 research highlight platform
guideline: 8 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 952 Mendeley

So far, Altmetric has seen 4 posts from 4 blogs.

Neoadjuvant celmiplimab is associated with pathologic response in cutaneous squamous cell carcinoma

Physician's Weekly, 23 Sep 2022

1. After neoadjuvant treatment with celmiplimab, half of the patients were found to have a complete pathological…

PD-1-Inhibitor für kutanes Plattenepithelkarzinom

medONLINE, 17 Jul 2019

Cemiplimab ist zugelassen zur Therapie von Patienten mit metastasiertem oder lokal fortgeschrittenem kutanen…

Immunotherapy Drug Cemiplimab Approved for Advanced Squamous Cell Skin Cancer

Cancer Currents: An NCI Cancer Research Blog, 19 Oct 2018

The Food and Drug Administration approved the immunotherapy drug cemiplimab (Libtayo) for an advanced form of cutaneous…

Richard Lehman’s journal reviews—30 July 2018

Latest BMJ blogs, 30 Jul 2018

Richard Lehman’s final review of the latest research in the top medical…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.